Jatin Narula
Overview
Explore the profile of Jatin Narula including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
322
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bhat H, Khan T, Puri A, Narula J, Mir A, Wani S, et al.
J Anesth Analg Crit Care
. 2024 Mar;
4(1):17.
PMID: 38429852
Background: The efficacy of the erector spinae plane (ESP) block in mitigating postoperative pain has been shown for a range of thoracic and abdominal procedures. However, there is a paucity...
2.
Moody A, Narula J, Maurer T
Clin Pharmacol Ther
. 2024 Jan;
115(5):1114-1121.
PMID: 38229405
Three sickle cell disease (SCD) treatment strategies, stabilizing oxygenated hemoglobin (oxyHb), lowering 2,3-BPG, and inducing fetal hemoglobin (HbF) expression aim to prevent red blood cell (RBC) sickling by reducing tense-state...
3.
Kapitanov G, Chabot J, Narula J, Roy M, Neubert H, Palandra J, et al.
Front Bioinform
. 2022 Oct;
1:731340.
PMID: 36303796
Quantitative modeling is increasingly utilized in the drug discovery and development process, from the initial stages of target selection, through clinical studies. The modeling can provide guidance on three major...
4.
Qiao W, Lin L, Young C, Narula J, Hua F, Matteson A, et al.
CPT Pharmacometrics Syst Pharmacol
. 2022 Apr;
11(7):880-893.
PMID: 35439371
Clinical responses of immuno-oncology therapies are highly variable among patients. Similar response variability has been observed in syngeneic mouse models. Understanding of the variability in the mouse models may shed...
5.
Maresca K, Chen J, Mathur D, Giddabasappa A, Root A, Narula J, et al.
Mol Imaging Biol
. 2021 Jun;
23(6):941-951.
PMID: 34143379
Purpose: A sensitive and specific imaging biomarker to monitor immune activation and quantify pharmacodynamic responses would be useful for development of immunomodulating anti-cancer agents. PF-07062119 is a T cell engaging...
6.
Chen W, Yang F, Wang C, Narula J, Pascua E, Ni I, et al.
MAbs
. 2021 Feb;
13(1):1871171.
PMID: 33557687
T-cell engaging biologics is a class of novel and promising immune-oncology compounds that leverage the immune system to eradicate cancer. Here, we compared and contrasted a bispecific diabody-Fc format, which...
7.
Root A, Guntas G, Katragadda M, Apgar J, Narula J, Chang C, et al.
MAbs
. 2021 Jan;
13(1):1850395.
PMID: 33459147
We report here the discovery and optimization of a novel T cell retargeting anti-GUCY2C x anti-CD3ε bispecific antibody for the treatment of solid tumors. Using a combination of hybridoma, phage...
8.
Gopalsamy A, Aulabaugh A, Barakat A, Beaumont K, Cabral S, Canterbury D, et al.
J Med Chem
. 2020 Dec;
64(1):326-342.
PMID: 33356244
Sickle cell disease (SCD) is a genetic disorder caused by a single point mutation (β6 Glu → Val) on the β-chain of adult hemoglobin (HbA) that results in sickled hemoglobin...
9.
Mathur D, Root A, Bugaj-Gaweda B, Bisulco S, Tan X, Fang W, et al.
Clin Cancer Res
. 2020 Jan;
26(9):2188-2202.
PMID: 31996389
Purpose: Gastrointestinal cancers remain areas of high unmet need despite advances in targeted and immunotherapies. Here, we demonstrate potent, tumor-selective efficacy with PF-07062119, a T-cell engaging CD3 bispecific targeting tumors...
10.
Kierzek A, Hickling T, Figueroa I, Kalvass J, Nijsen M, Mohan K, et al.
CPT Pharmacometrics Syst Pharmacol
. 2019 Sep;
8(11):773-776.
PMID: 31529677
No abstract available.